These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 10463574)

  • 1. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.
    Koesters R; Ridder R; Kopp-Schneider A; Betts D; Adams V; Niggli F; Briner J; von Knebel Doeberitz M
    Cancer Res; 1999 Aug; 59(16):3880-2. PubMed ID: 10463574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
    Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
    Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
    J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Codon 45 of the beta-catenin gene, a specific mutational target site of Wilms' tumor.
    Kusafuka T; Miao J; Kuroda S; Udatsu Y; Yoneda A
    Int J Mol Med; 2002 Oct; 10(4):395-9. PubMed ID: 12239584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules.
    Nakatani Y; Masudo K; Miyagi Y; Inayama Y; Kawano N; Tanaka Y; Kato K; Ito T; Kitamura H; Nagashima Y; Yamanaka S; Nakamura N; Sano J; Ogawa N; Ishiwa N; Notohara K; Resl M; Mark EJ
    Mod Pathol; 2002 Jun; 15(6):617-24. PubMed ID: 12065775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target genes of the WNT/beta-catenin pathway in Wilms tumors.
    Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M
    Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis.
    Hollmann CA; Kittrell FS; Medina D; Butel JS
    Oncogene; 2001 Nov; 20(52):7645-57. PubMed ID: 11753642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas.
    Schwartz DR; Wu R; Kardia SL; Levin AM; Huang CC; Shedden KA; Kuick R; Misek DE; Hanash SM; Taylor JM; Reed H; Hendrix N; Zhai Y; Fearon ER; Cho KR
    Cancer Res; 2003 Jun; 63(11):2913-22. PubMed ID: 12782598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia.
    Chen YW; Jeng YM; Yeh SH; Chen PJ
    Hepatology; 2002 Oct; 36(4 Pt 1):927-35. PubMed ID: 12297840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer.
    Clements WM; Wang J; Sarnaik A; Kim OJ; MacDonald J; Fenoglio-Preiser C; Groden J; Lowy AM
    Cancer Res; 2002 Jun; 62(12):3503-6. PubMed ID: 12067995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma.
    Shiina H; Igawa M; Breault J; Ribeiro-Filho L; Pookot D; Urakami S; Terashima M; Deguchi M; Yamanaka M; Shirai M; Kaneuchi M; Kane CJ; Dahiya R
    Clin Cancer Res; 2003 Jun; 9(6):2121-32. PubMed ID: 12796377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
    Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
    Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chibby, a novel antagonist of the Wnt pathway, is not involved in Wilms tumor development.
    Zirn B; Wittmann S; Graf N; Gessler M
    Cancer Lett; 2005 Mar; 220(1):115-20. PubMed ID: 15737694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas.
    Bläker H; Helmchen B; Bönisch A; Aulmann S; Penzel R; Otto HF; Rieker RJ
    Scand J Gastroenterol; 2004 Aug; 39(8):748-53. PubMed ID: 15513360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
    Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
    Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of the Wnt pathway in the pathology of human cancers.
    Karim R; Tse G; Putti T; Scolyer R; Lee S
    Pathology; 2004 Apr; 36(2):120-8. PubMed ID: 15203747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer.
    González-Sancho JM; Aguilera O; García JM; Pendás-Franco N; Peña C; Cal S; García de Herreros A; Bonilla F; Muñoz A
    Oncogene; 2005 Feb; 24(6):1098-103. PubMed ID: 15592505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor.
    Fujimori M; Ikeda S; Shimizu Y; Okajima M; Asahara T
    Cancer Res; 2001 Sep; 61(18):6656-9. PubMed ID: 11559529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
    Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
    Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Menin promotes the Wnt signaling pathway in pancreatic endocrine cells.
    Chen G; A J; Wang M; Farley S; Lee LY; Lee LC; Sawicki MP
    Mol Cancer Res; 2008 Dec; 6(12):1894-907. PubMed ID: 19074834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.